[Diagnosis and management of patients with pheochromocytoma/paraganglioma: Consensus of experts of the Russian Medical Society for Arterial Hypertension and the Multidisciplinary Group for the Diagnosis and Treatment of Neuroendocrine Tumors].

Pub Date : 2024-07-30 DOI:10.26442/00403660.2024.07.202779
N V Blinova, I A Ilovayskaya, N M Chikhladze, A Y Lugovskaya, T A Britvin, L E Gurevich, L N Nefedova, V E Shikina, I E Chazova
{"title":"[Diagnosis and management of patients with pheochromocytoma/paraganglioma: Consensus of experts of the Russian Medical Society for Arterial Hypertension and the Multidisciplinary Group for the Diagnosis and Treatment of Neuroendocrine Tumors].","authors":"N V Blinova, I A Ilovayskaya, N M Chikhladze, A Y Lugovskaya, T A Britvin, L E Gurevich, L N Nefedova, V E Shikina, I E Chazova","doi":"10.26442/00403660.2024.07.202779","DOIUrl":null,"url":null,"abstract":"<p><p>The understanding of the nature of catecholamine-secreting tumors has changed significantly in recent years, affecting terminology and classification. Phaeochromocytoma/paraganglioma (PCC/PG) is a rare neuroendocrine tumor from chromaffin tissue that produces and secretes catecholamines. The incidence of PCC/PG is relatively low, with 2-8 cases per 1 million population per year; among patients with arterial hypertension, their prevalence is 0.2-0.6%. However, delayed diagnosis of PCC/PG is associated with a high risk of cardiovascular complications and a high mortality rate. The consensus presents the clinical manifestations of the disease with an emphasis on the course of arterial hypertension as the most common symptom in PCC/PG; modern ideas about the features of diagnosis, aspects of preoperative preparation, treatment, and follow-up of patients with PCC/PG are considered.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2024.07.202779","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The understanding of the nature of catecholamine-secreting tumors has changed significantly in recent years, affecting terminology and classification. Phaeochromocytoma/paraganglioma (PCC/PG) is a rare neuroendocrine tumor from chromaffin tissue that produces and secretes catecholamines. The incidence of PCC/PG is relatively low, with 2-8 cases per 1 million population per year; among patients with arterial hypertension, their prevalence is 0.2-0.6%. However, delayed diagnosis of PCC/PG is associated with a high risk of cardiovascular complications and a high mortality rate. The consensus presents the clinical manifestations of the disease with an emphasis on the course of arterial hypertension as the most common symptom in PCC/PG; modern ideas about the features of diagnosis, aspects of preoperative preparation, treatment, and follow-up of patients with PCC/PG are considered.

分享
查看原文
[嗜铬细胞瘤/副神经胶质瘤患者的诊断和治疗:俄罗斯动脉高血压医学会和神经内分泌肿瘤诊断与治疗多学科小组专家共识]。
近年来,人们对儿茶酚胺分泌性肿瘤性质的认识发生了重大变化,对术语和分类也产生了影响。绒毛膜细胞瘤/副神经胶质瘤(PCC/PG)是一种罕见的神经内分泌肿瘤,来自绒毛膜组织,能产生和分泌儿茶酚胺。PCC/PG 的发病率相对较低,每年每 100 万人口中有 2-8 例;在动脉高血压患者中,其发病率为 0.2-0.6%。然而,PCC/PG 的延迟诊断与心血管并发症的高风险和高死亡率有关。本共识介绍了该疾病的临床表现,重点是作为 PCC/PG 最常见症状的动脉高血压的病程;考虑了有关 PCC/PG 患者的诊断特点、术前准备、治疗和随访等方面的现代观点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信